In brief, a no-deal Brexit would imply an unprecedented disruption of the European pharmaceuticals market in terms of research, regulation, manufacture, and trade in biopharmaceuticals. It would even impact drug prices as reference pricing schemes throughout the E.U. would need to be altered.
Brexit’s Disruptive Impact On U.K. And European Prescription Drug Market
